New antibody drug shows promise in early cancer trial
NCT ID NCT06929195
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested a new drug called TQB2210 in 16 people with advanced cancers that had not responded to other treatments. The drug is a lab-made antibody that targets a specific protein (FGFR2b) on cancer cells to block their growth. The main goals were to find a safe dose and check for early signs of tumor shrinkage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMOURS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400030, China
-
Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University)
Changsha, Hunan, 410005, China
-
Shanghai Tenth Hospital, Tongji University
Shanghai, Shanghai Municipality, 200032, China
-
The Henan Cancer Hospital
Zhengzhou, Henan, 450008, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
-
ZhuJiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.